Skip to content

Retinal Venous Pressure and ET-1 in Patients With Diabetes Mellitus

Measurement of Retinal Venous Pressure and Endothelin-1 in Patients With Diabetes Mellitus

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01771835
Enrollment
20
Registered
2013-01-18
Start date
2011-08-31
Completion date
2012-11-30
Last updated
2013-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

diabetes mellitus, retinal venous pressure, endothelin-1

Brief summary

Measurement of the circulation in patients with diabetes mellitus and establish a link between retinal venous pressure (RVP) and endothelin (ET-1)levels.

Detailed description

Diabetic retinopathy and maculopathy are the main causes of visual loss. Hyperglycemia as the main risk factor of diabetic retinopathy induced damage to retinal capillaries. These in turn lead to hypoxia in the tissue and promote the release of VEGF (vascular endothelial growth factor) , which in turn increases the vascular pathology. Simultaneously, there is an increased expression of endothelin (ET-1). Endothelin increases vascular tone and regulates the micro-and macro-vascular remodeling. In ocular blood flow perfusion pressure plays an important role. While in healthy eyes a spontaneous retinal venous pulsation is frequently observed, this is significantly less frequent in diseased eyes. An increased venous pressure lowers the ocular perfusion pressure, and increases the transmural pressure. A measurement of the retinal venous pressure and the hormone ET-1 in the blood will give us a better knowledge of the circulatory changes and their relationship to diabetes.

Interventions

None listed

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* diabetes mellitus type I or II * no diabetic retinopathy

Exclusion criteria

* known diabetic retinopathy * acute or chronic inflammation of the eyes * narrow angle glaucoma * minority

Design outcomes

Primary

MeasureTime frame
Quantification of retinal venous pressure (RVP)30 minutes

Secondary

MeasureTime frame
Quantification of ET-1 in correlation with RVP30 minutes

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026